SENATE DOCKET, NO. 685        FILED ON: 1/15/2019

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 603

 

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

John F. Keenan

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to the care and treatment of patients with mitochondrial disease.

_______________

PETITION OF:

 

Name:

District/Address:

 

John F. Keenan

Norfolk and Plymouth

 

Crystal Evans

 

 

Walter F. Timilty

Norfolk, Bristol and Plymouth

1/29/2019

Elizabeth A. Poirier

14th Bristol

1/31/2019

John J. Lawn, Jr.

10th Middlesex

1/31/2019

Mark J. Cusack

5th Norfolk

1/31/2019

Paul McMurtry

11th Norfolk

1/31/2019

Patrick M. O'Connor

Plymouth and Norfolk

1/31/2019

Antonio F. D. Cabral

13th Bristol

1/31/2019

Thomas M. Stanley

9th Middlesex

2/1/2019

Brian M. Ashe

2nd Hampden

2/1/2019

Joan B. Lovely

Second Essex

12/17/2019


SENATE DOCKET, NO. 685        FILED ON: 1/15/2019

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 603

By Mr. Keenan, a petition (accompanied by bill, Senate, No. 603) of John F. Keenan, Crystal Evans, Walter F. Timilty, Elizabeth A. Poirier and other members of the General Court for legislation relative to the care and treatment of patients with mitochondrial disease.  Financial Services.

 

The Commonwealth of Massachusetts

 

_______________

In the One Hundred and Ninety-First General Court
(2019-2020)

_______________

 

An Act relative to the care and treatment of patients with mitochondrial disease.

 

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1. Chapter 32A of the General Laws is hereby amended by inserting after Section 17K the following section:-

Section 17L. The commission shall provide to any active or retired employee of the commonwealth or spouse/dependent who is insured under the group insurance commission, coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 2. Chapter 175 of the General Laws is hereby amended by inserting after Section 47DD the following section:-

Section 47EE. Any policy, contract, agreement, plan or certificate of insurance issued, delivered or renewed within the commonwealth shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 3. Chapter 176A of the General Laws is hereby amended by inserting after Section 8EE the following section:-

Section 8FF. Any contract between a subscriber and a corporation under an individual or group hospital service plan delivered, issued or renewed within the commonwealth shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 4. Chapter 176B of the General Laws is hereby amended by inserting after Section 4FF the following section:-

Section 4GG. Any subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 5. Chapter 176G of the General Laws is hereby amended by inserting after Section 4X the following section:-

Section 4Y. Any individual or group health maintenance contract shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.